<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diversion colitis: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diversion colitis: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diversion colitis: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bo Shen, MD, AGAF, FACG, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Thomas Lamont, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 22, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1184090454">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diversion colitis or diversion proctitis is a nonspecific inflammatory disorder that occurs in segments of the colon and rectum that are diverted from the fecal stream by surgery (eg, creation of a loop colostomy/ileostomy or an end colostomy/ileostomy with closure of the distal colon segment [eg, Hartmann's procedure]).
        </p>
        <p>
         The construction of ileostomy or colostomy with fecal diversion is routinely performed in patients who have medically refractory benign or malignant colorectal diseases, those who undergo distal bowel resection and anastomosis, or reconstruction in the distal bowel. Diversion colitis is characterized by inflammation of the defunctionalized, bypassed colon following surgery [
         <a href="#rid1">
          1,2
         </a>
         ]. Most patients with diversion colitis are asymptomatic, but in a small proportion of patients, symptoms can significantly impact quality of life [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         This topic will review the management of diversion colitis. The epidemiology, clinical manifestations and diagnosis of diversion colitis are discussed in detail, separately. (See
         <a class="medical medical_review" href="/z/d/html/4075.html" rel="external">
          "Diversion colitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1613705801">
         <span class="h1">
          SYMPTOMATIC PATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3885190409">
         <span class="h2">
          Surgical restoration of intestinal continuity
         </span>
         <span class="headingEndMark">
          —
         </span>
         In symptomatic patients with diversion colitis, restoring intestinal continuity by surgical reanastomosis is the treatment of choice as it is associated with a high rate of resolution of inflammation resulting from fecal diversion (
         <a class="graphic graphic_algorithm graphicRef140048" href="/z/d/graphic/140048.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef118678" href="/z/d/graphic/118678.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. In patients who are candidates for surgery, early reanastomosis is preferred because, with a delay in reestablishment of bowel continuity, symptoms often become more frequent and severe, and there is a progressive decrease in capacity and involution of the defunctionalized anorectum [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         In patients with Crohn disease, if the distal segment was not involved endoscopically and histologically before diversion, early reanastomosis will improve symptoms and may help avert stricture formation in the lumen of diverted colorectum [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4075.html" rel="external">
          "Diversion colitis: Clinical manifestations and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         If it is unclear if the symptoms are due to diversion colitis or active inflammatory bowel disease (IBD) in the diverted colon, treatment response to a short-chain fatty acid (SCFA) enema can help distinguish between them as a symptomatic response to SCFA enemas supports the diagnosis of diversion colitis. In these patients, a response to SCFA enemas should be followed by surgical reanastomosis [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Short-chain fatty acid enemas'
         </a>
         below.)
        </p>
        <p>
         In patients with active distal IBD that precludes surgical restoration of intestinal continuity, medical management of diversion colitis is indicated (see
         <a class="local">
          'Initial treatment'
         </a>
         below). In a study of 138 patients with fecal diversion for severe perianal Crohn disease, 30 (22 percent) achieved stoma closure, 45 (33 percent) kept a stoma with diverted rectum in place, and 63 (45 percent) had to have proctectomy with permanent stoma during a mean follow-up of 5.7 years [
         <a href="#rid8">
          8
         </a>
         ]. Factors that predicted inability to achieve stoma closure were disease involvement of the rectum and presence of setons of perianal disease [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Although randomized trials are lacking, in small observational studies, reanastomosis has been reported to be curative within three months and may also restore anal sphincter function [
         <a href="#rid9">
          9,10
         </a>
         ]. However, the reestablishment of bowel continuity may not lead to complete resolution of endoscopic and histologic inflammation, the clinical significance of which is unclear [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2046476276">
         <span class="h2">
          Patients who cannot undergo surgical reanastomosis
         </span>
        </p>
        <p class="headingAnchor" id="H1008954292">
         <span class="h3">
          Initial treatment
         </span>
        </p>
        <p class="headingAnchor" id="H4290069519">
         <span class="h4">
          Short-chain fatty acid enemas
         </span>
         <span class="headingEndMark">
          —
         </span>
         SCFA enemas are used as initial therapy in patients with diversion colitis who are unable or unwilling to undergo surgery (
         <a class="graphic graphic_algorithm graphicRef140048" href="/z/d/graphic/140048.html" rel="external">
          algorithm 1
         </a>
         ). We also use SCFA enemas in patients with known distal IBD in whom the diagnosis of diversion colitis is unclear as a response to SCFA enemas supports the diagnosis of diversion colitis [
         <a href="#rid12">
          12
         </a>
         ]. SCFA enemas require preparation at compounding pharmacies. It can also be expensive and produce an odor resulting in poor adherence [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4075.html" rel="external">
          "Diversion colitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and duration
         </strong>
         – Various dosing regimens of SCFA enemas for induction have been reported in the literature, ranging from 10 mL once or twice a day to 60 mL enema twice a day for four weeks [
         <a href="#rid4">
          4,13-16
         </a>
         ]. The author uses the following composition for SCFA enemas:
         <a class="drug drug_general" data-topicid="9926" href="/z/d/drug information/9926.html" rel="external">
          sodium acetate
         </a>
         (60 mmol), sodium propionate (30 mmol), and sodium n-butyrate (40 mmol) with additional sodium chloride (22 mmol) to yield an osmolality of 280 to 290 mosmol/L, which is similar to plasma. The pH is adjusted to 7.4 with sodium hydroxide or hydrochloric acid. A 60 mL enema is instilled into the diverted distal bowel once daily for up to four weeks. In patients whose symptoms improve but flare with discontinuation, SCFA enemas are continued at a reduced dose as long-term maintenance (eg, one enema daily and then three times a week at bedtime).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The initial observation that the diverted segment of the colorectum contained negligible concentrations of SCFAs, and response in four adult patients to administration of D-glucose in a pilot study, provided the rationale for the use of SCFA [
         <a href="#rid7">
          7
         </a>
         ]. Other studies in adults have had a small sample size and results have been conflicting [
         <a href="#rid7">
          7,13,14,17
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a prospective study that included 13 patients with diversion colitis, treatment with SCFA for 14 days was not associated with endoscopic or histologic remission [
         <a href="#rid14">
          14
         </a>
         ]. However, this study was limited by the short duration of treatment. In addition, most patients had only mild endoscopic and histologic changes of diversion colitis at baseline.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A randomized crossover trial included 10 patients with IBD (nine Crohn disease and one ulcerative colitis) who had undergone colectomy with creation of a Hartmann pouch a median of 15 months prior to the start of the trial. Patients were treated with SCFA instillation or placebo for three weeks. In this study, treatment with SCFA was not associated with an improvement in inflammation [
         <a href="#rid13">
          13
         </a>
         ]. However, most patients had severe inflammation by endoscopy and histology that might have been more consistent with the underlying IBD than with diversion colitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In another randomized trial, 20 patients with fecal diversion (more than 30 days) for IBD, colorectal cancer, or diverticular disease were assigned to sodium butyrate enemas or
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         enemas [
         <a href="#rid15">
          15
         </a>
         ]. Of the 17 patients with diversion colitis/proctitis who completed the trial, there was a significant improvement in endoscopy scores in the treatment but not the control group. Histologic scores of inflammation in both groups were numerically increased at the end of the trial. Mucosal atrophy scores were reduced or unchanged in SCFA group but increased in the control group over the course of the study. However, this difference was not statistically significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It has been suggested that children diverted for reasons other than IBD seem to respond more consistently to SCFA enemas than adults; however, few observational studies have been published and the long-term response to SCFAs is unknown [
         <a href="#rid4">
          4,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H311527520">
         <span class="h4">
          5-aminosalicylic acid (5-ASA)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients whose symptoms fail to improve after four weeks of treatment with SCFA enemas, we suggest topical 5-aminosalicylic acids (ASAs;
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         ) (
         <a class="graphic graphic_algorithm graphicRef140048" href="/z/d/graphic/140048.html" rel="external">
          algorithm 1
         </a>
         ). In patients with diversion colitis who have underlying IBD, regardless of whether IBD involves the diverted segment, we use topical 5-ASAs in conjunction with SCFAs [
         <a href="#rid18">
          18
         </a>
         ]. Topical 5-ASAs are widely available as suppositories or enemas (eg, mesalamine suppository 1 gram twice daily, mesalamine retention enema 4 grams twice daily). However, evidence to support topical 5-ASA use in diversion colitis is limited to case reports [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2535071980">
         <span class="h3">
          Persistent symptoms
         </span>
        </p>
        <p class="headingAnchor" id="H704217308">
         <span class="h4">
          Topical glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of glucocorticoids should be limited to patients with diversion colitis who do not respond to or only partially respond to therapy with SCFA enemas and topical
         <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">
          mesalamine
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef140048" href="/z/d/graphic/140048.html" rel="external">
          algorithm 1
         </a>
         ). For patients who completely fail to respond to SCFA and/or topical 5-ASA agents, a four-week course of topical corticosteroids can be used as the sole agent. For patients who have a partial response to SCFA and/or topical 5-ASA agents, topical corticosteroids can be used in addition to the existing regimen [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Topical preparations of glucocorticoids include enemas, suppositories, and foam (eg,
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         enema 100 mg twice daily, hydrocortisone suppository 30 mg twice daily, hydrocortisone foam 10 percent 90 mg twice daily, and
         <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">
          budesonide
         </a>
         foam 2 mg daily). Topical steroids have not been systemically studied for the treatment of diversion colitis and their use is based on their efficacy in patients with other forms of colitis. In this author's experience, patients with diversion colitis/proctitis along with underlying IBD may have a more favorable response to the topical glucocorticoid therapy than those without underlying IBD. However, it is important to note that adrenal suppression and other systemic adverse effects do occur in patients with long-term use of topical glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids", section on 'Organ-based toxicity of systemic glucocorticoids'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3871702350">
         <span class="h4">
          Surgical proctectomy in selected patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proctectomy or sigmoid colectomy with proctectomy is reserved for patients with refractory symptoms of diversion proctitis or colitis. In patients with colitis-associated dysplasia in the diverted bowel, this is definitive treatment for the diversion colitis [
         <a href="#rid21">
          21,22
         </a>
         ]. However, completion colectomy, proctectomy, and pouch excision carry a risk for anal stump leak or abscess [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1898698072">
         <span class="h3">
          Therapies with uncertain benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several approaches that have been evaluated in small studies of patients with diversion colitis that we do not routinely recommend due to lack of sufficient evidence of benefit. However, they may be used as adjunctive nonsurgical options for patients with refractory symptoms after consideration of potential harm, cost, and patient preference.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Probiotics
         </strong>
         – In a randomized controlled trial, 69 patients with diversion colitis after undergoing loop ileostomy closure for colorectal cancer were assigned to treatment with administration of a probiotic (consisting of four strains of Lactobacillus, three strains of Bifidobacterium, and one strain of Streptococcus) via the efferent limb of stoma or placebo for 20 days. Improvement in endoscopic and histologic inflammation before stoma closure and symptoms of diversion colitis after stoma closure were observed in a significantly higher number of patients in the study group than that in the control group [
         <a href="#rid24">
          24
         </a>
         ]. However, the pre-stoma closure probiotic stimulation of the diverted bowel failed to improve postoperative ileus, time-to-tolerating diet, passage of flatus and stools, or length of hospital stay for the stoma closure surgery. The role of probiotics in the treatment of diversion colitis in patients with underling IBD has not been systemically evaluated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fecal microbiota transplantation
         </strong>
         – Autologous fecal microbiota transplantation has been associated with endoscopic remission in patients with diversion colitis in small observational studies of patients without underlying IBD [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         –
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         , an anti-tumor necrosis factor agent used in the treatment of IBD, has been used to treat refractory diversion colitis in a patient without underlying IBD [
         <a href="#rid28">
          28,29
         </a>
         ]. Other topical agents, which showed efficacy in reduction of mucosal inflammation or pro-inflammatory mediators, include
         <a class="drug drug_general" data-topicid="9953" href="/z/d/drug information/9953.html" rel="external">
          sucralfate
         </a>
         (in an animal model) [
         <a href="#rid30">
          30,31
         </a>
         ], heparin [
         <a href="#rid32">
          32
         </a>
         ], dietary fiber [
         <a href="#rid33">
          33
         </a>
         ], curcumin enema [
         <a href="#rid34">
          34
         </a>
         ], and leukocytapheresis [
         <a href="#rid35">
          35
         </a>
         ]. High-concentration dextrose (50 percent) has been used for management of refractory bleeding (
         <a class="graphic graphic_picture graphicRef127452" href="/z/d/graphic/127452.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid36">
          36
         </a>
         ] due to diversion colitis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2232965060">
         <span class="h1">
          ASYMPTOMATIC PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a lack of consensus on whether asymptomatic patients who are not at high risk of colorectal cancer due to inflammatory bowel disease (IBD) or other risk factors require treatment of endoscopic and/or histologic chronic inflammation. Inflammation may persist in non-IBD patients, even after bowel continuity is restored, but the clinical significance of this is unclear [
         <a href="#rid11">
          11
         </a>
         ]. In asymptomatic patients with fecal diversion for more than one year, we perform yearly lower gastrointestinal endoscopy to monitor disease activity, remove bezoars or polyps, and treat strictures, if present. Despite the risk of procedure-associated bowel perforation, bleeding, or bacterial translocation, the author treats diversion-associated strictures for relief of symptoms and to facilitate surveillance for dysplasia. However, the procedure is preferably performed at centers of excellence with endoscopic and colorectal surgery expertise. Topical treatment of diversion colitis (eg, short-chain fatty acid enemas) may be offered to asymptomatic patients with severe endoscopic inflammation to reduce the risk for bowel wall fibrosis and, theoretically, neoplasia.
        </p>
        <p class="headingAnchor" id="H3875408814">
         <span class="h1">
          PREVENTION AND MANAGEMENT OF COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3416340314">
         <span class="h2">
          Colorectal cancer surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not perform routine colorectal cancer (CRC) surveillance in the diverted segment unless the underlying condition for which the surgery was performed is associated with an increased risk of cancer. The risk for the development of dysplasia or CRC in the diverted colorectum in patients without other risk factors for CRC (eg, a history of CRC, a hereditary colorectal cancer syndrome, underlying inflammatory bowel disease [IBD]) is low.
        </p>
        <p>
         Surveillance endoscopy of the diverted large bowel is indicated only in patients with permanent fecal diversion and one of the following risk factors that place them at high risk for dysplasia or CRC [
         <a href="#rid21">
          21,37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preoperative diagnosis of colitis-associated neoplasia in the segment of bowel, with or without endoscopic therapy for the neoplasia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long history (&gt;8 years) of ulcerative colitis or Crohn colitis involving the colon and rectum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent primary sclerosing cholangitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large bowel strictures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pelvic radiation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal history of colon cancer or hereditary colorectal cancer syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CRC in a first-degree relative diagnosed at age 50 years or younger
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biopsy protocol
         </strong>
         – Four random biopsies every 10 cm should be taken using a modified Seattle protocol. Additionally, any endoscopically visible lesion should be biopsied or resected for histologic evaluation. The role of chromoendoscopy in the surveillance of colitis-associated neoplasia in the diverted pouch has not been established as the friability of the mucosa makes the application of dye challenging. Endoscopic polypectomy can be safely performed in patients with a diverted colon. However, we avoid endoscopic mucosal resection and submucosal dissection for flat lesions due to the risk of perforation (
         <a class="graphic graphic_picture graphicRef140347" href="/z/d/graphic/140347.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2670.html" rel="external">
          "Chromoendoscopy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surveillance interval
         </strong>
         – Yearly surveillance endoscopy of the diverted large bowel or ileal pouch is recommended in patients with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Precolectomy diagnosis of colorectal neoplasia in IBD or non-IBD patients
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of dysplasia of the pouch
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Familial adenomatous polyposis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In all other patients at high-risk for dysplasia or CRC, surveillance endoscopy is recommended every one to three years [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Temporary bacterial translocation can occur in patients with a long-term diverted bowel who undergo endoscopic or surgical procedure of the segment of bowel. Spontaneous pyogenic liver abscess has been reported in a patient with precolectomy ulcerative colitis and diverted ileal pouch [
         <a href="#rid38">
          38
         </a>
         ]. However, routine antibiotic prophylaxis in patients with diversion colitis undergoing endoscopic or surgical intervention in the diverted segment is controversial [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3477243570">
         <span class="h2">
          Endoscopic therapy of diversion-associated strictures and fecal bezoars
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on the location and severity, diversion-associated strictures may require dilatation (digital, bougie, or endoscopic balloon dilatation) or endoscopic stricturotomy (
         <a class="graphic graphic_diagnosticimage graphicRef118677" href="/z/d/graphic/118677.html" rel="external">
          image 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef140346" href="/z/d/graphic/140346.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid39">
          39,40
         </a>
         ]. Large, symptomatic bezoars can be removed endoscopically (
         <a class="graphic graphic_picture graphicRef139433" href="/z/d/graphic/139433.html" rel="external">
          picture 4
         </a>
         ). The endoscopic management of strictures is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">
          "Surgical management of Crohn disease", section on 'Endoscopic dilatation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1613322109">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms of diversion colitis and goals of treatment
         </strong>
         – Diversion colitis is an inflammatory process that occurs in segments of the colorectum that are diverted from the fecal stream by surgery. Most patients with histologically evident diversion colitis are asymptomatic. The most common symptoms in adults are tenesmus, urgency, bloody and/or mucus discharge, and abdominal pain. Persistent inflammation and long-term non-use may result in stricture formation in the diverted bowel and accumulation of mucus materials with formation of a bezoar. The goal of treatment is relief of symptoms. (See
         <a class="medical medical_review" href="/z/d/html/4075.html" rel="external">
          "Diversion colitis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Observation of asymptomatic patients
         </strong>
         – There is a lack of consensus on whether asymptomatic patients who are not at high risk of colorectal cancer due to inflammatory bowel disease (IBD) or other risk factors require treatment of endoscopic and/or histologic inflammation. Inflammation may persist in non-IBD patients, even after bowel continuity is restored, but the clinical significance of this is unclear. In asymptomatic patients with fecal diversion for more than one year, we perform yearly lower gastrointestinal endoscopy to monitor disease activity, remove bezoars or polyps, and treat strictures, if present. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical restoration of intestinal continuity
         </strong>
         – In patients with symptomatic diversion colitis in whom restoration of intestinal continuity is feasible, we suggest surgical reanastomosis rather than medical management (
         <a class="graphic graphic_algorithm graphicRef140048" href="/z/d/graphic/140048.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In patients who are candidates for surgery, early reanastomosis is preferred because, with a delay in reestablishment of bowel continuity, symptoms often become more frequent and severe, and there is a progressive decrease in capacity and involution of the defunctionalized anorectum. (See
         <a class="local">
          'Surgical restoration of intestinal continuity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who are not candidates for restoration of intestinal continuity
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Short-chain fatty acid enemas
         </strong>
         : For symptomatic patients who are not candidates for reanastomosis, we suggest a trial of short-chain fatty acid (SCFA) enemas (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Topical 5-ASA agents
         </strong>
         : For patients who do not respond to a trial of SCFA enemas, we suggest treatment with topical 5-aminosalicylic acid (ASA) agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In patients with diversion colitis who have underlying IBD, regardless of whether IBD involves the diverted segment, we use topical 5-ASAs in conjunction with SCFAs.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Topical glucocorticoids in selected patients
         </strong>
         : In patients who fail to respond completely to SCFA and/or topical 5-ASA agents, we use topical glucocorticoids. Topical glucocorticoids may be particularly useful in patients with underlying IBD. However, long-term use should be avoided to avoid glucocorticoid side effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Proctectomy or sigmoid colectomy with proctectomy for refractory symptoms
         </strong>
         : We reserve proctectomy or sigmoid colectomy with proctectomy for patients with refractory symptoms of diversion proctitis or colitis. Completion colectomy, proctectomy, and pouch excision carry a risk for anal stump leak or abscess formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of colorectal cancer risk
         </strong>
         – The risk for the development of dysplasia or colorectal cancer (CRC) in the diverted colorectum in patients without other risk factors for CRC (eg, a history of CRC, a hereditary colorectal cancer syndrome, underlying IBD) is low. (See
         <a class="local">
          'Colorectal cancer surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Surveillance endoscopy of the diverted bowel is indicated only in patients with permanent fecal diversion and one of the following risk factors that place them at high risk for dysplasia or CRC:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preoperative diagnosis of colitis-associated neoplasia in the segment of bowel, with or without endoscopic therapy for the neoplasia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Long history (&gt;8 years) of ulcerative colitis or Crohn colitis involving the colon and rectum
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Concurrent primary sclerosing cholangitis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large bowel strictures
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pelvic radiation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of CRC in a first-degree relative diagnosed at age 50 years or younger
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Familial adenomatous polyposis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2093806707">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dr. Richard I. Breuer, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Glotzer DJ, Glick ME, Goldman H. Proctitis and colitis following diversion of the fecal stream. Gastroenterology 1981; 80:438.
          </a>
         </li>
         <li class="breakAll">
          Morson BC, Dawson IM. Gastrointestinal Pathology, 1st ed, Blackwell Scientific Publications, London 1972. p.485.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son DN, Choi DJ, Woo SU, et al. Relationship between diversion colitis and quality of life in rectal cancer. World J Gastroenterol 2013; 19:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pal K, Tinalal S, Al Buainain H, Singh VP. Diversion proctocolitis and response to treatment with short-chain fatty acids--a clinicopathological study in children. Indian J Gastroenterol 2015; 34:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korelitz BI, Cheskin LJ, Sohn N, Sommers SC. The fate of the rectal segment after diversion of the fecal stream in Crohn's disease: its implications for surgical management. J Clin Gastroenterol 1985; 7:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roe AM, Warren BF, Brodribb AJ, Brown C. Diversion colitis and involution of the defunctioned anorectum. Gut 1993; 34:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harig JM, Soergel KH, Komorowski RA, Wood CM. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med 1989; 320:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu J, Valente MA, Remzi FH, Stocchi L. Factors affecting the fate of faecal diversion in patients with perianal Crohn's disease. Colorectal Dis 2015; 17:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korelitz BI, Cheskin LJ, Sohn N, Sommers SC. Proctitis after fecal diversion in Crohn's disease and its elimination with reanastomosis: implications for surgical management. Report of four cases. Gastroenterology 1984; 87:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zieliński T, Czyżewski P, Szczepkowski M. The usefulness of anorectal manometry in patients with a stoma before and after surgery to restore the continuity of the gastrointestinal tract. Pol Przegl Chir 2016; 88:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczepkowski M, Banasiewicz T, Kobus A. Diversion colitis 25 years later: the phenomenon of the disease. Int J Colorectal Dis 2017; 32:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen B, Kochhar GS, Rubin DT, et al. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol 2022; 7:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schauber J, Bark T, Jaramillo E, et al. Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum. Scand J Gastroenterol 2000; 35:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillemot F, Colombel JF, Neut C, et al. Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. Dis Colon Rectum 1991; 34:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luceri C, Femia AP, Fazi M, et al. Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial. Dig Liver Dis 2016; 48:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zundler S, Dietz L, Matzel KE, et al. Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application. Am J Gastroenterol 2018; 113:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiely EM, Ajayi NA, Wheeler RA, Malone M. Diversion procto-colitis: response to treatment with short-chain fatty acids. J Pediatr Surg 2001; 36:1514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995; 40:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tripodi J, Gorcey S, Burakoff R. A case of diversion colitis treated with 5-aminosalicylic acid enemas. Am J Gastroenterol 1992; 87:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsumoto S, Mashima H. Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis. Case Rep Gastroenterol 2016; 10:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ten Hove JR, Bogaerts JMK, Bak MTJ, et al. Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lightner AL, Buhulaigah H, Zaghiyan K, et al. Is Intestinal Diversion an Effective Treatment for Distal Crohn's Disease? Inflamm Bowel Dis 2022; 28:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bremers AJ, van Laarhoven KJ, van der Kolk BM, et al. Transanal endoscopic microsurgery approach for rectal stump resection as an alternative to transperitoneal stump resection. Br J Surg 2013; 100:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez-Padilla Á, Morales-Martín G, Pérez-Quintero R, et al. Diversion Colitis: Macro and Microscopic Findings after Probiotics Stimulation. Biology (Basel) 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gundling F, Tiller M, Agha A, et al. Successful autologous fecal transplantation for chronic diversion colitis. Tech Coloproctol 2015; 19:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahue CA, Chaudhry V, Mantilla N. Autologous fecal transplant for the treatment of microcolon due to diversion colitis. Tech Coloproctol 2022; 26:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tominaga K, Tsuchiya A, Mizusawa T, et al. Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis. DEN open 2022; 2:e63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alves Junior AJT, Pereira JA, Ávila MG, et al. Tissue content of metalloproteinase-9 and collagen in the colon with and without fecal stream after intervention with infliximab in rats subjected to Hartmann's surgery. Acta Cir Bras 2021; 36:e360401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kido M, Tamura R, Yasui Y, Okajima H. Novel application of infliximab for diversion colitis. BMJ Case Rep 2021; 14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaim FM, Sato DT, Rodrigues MR, et al. Evaluation of the application of enemas containing sucralfate in tissue content of neutral and acid mucins in experimental model of diversion colitis. Acta Cir Bras 2014; 29:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato DT, Campos FG, Kotze PG, et al. Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and ?-catenin in colonic mucosa without fecal stream. Acta Cir Bras 2021; 36:e361007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarenga V Jr, Pacheco RG, Esposito CC, et al. Ascidian (chordate-tunicate) and mammalian heparin enemas attenuate experimental diversion colitis. Surgery 2014; 155:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira-Neto JP, de Aguilar-Nascimento JE. Intraluminal irrigation with fibers improves mucosal inflammation and atrophy in diversion colitis. Nutrition 2004; 20:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadri CJ, Pereira JA, Campos FG, et al. Anti-inflammatory effects of enemas containing an oily extract of curcumin in an experimental model of diversion colitis. Histol Histopathol 2017; 32:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe C, Hokari R, Miura S. Chronic antibiotic-refractory diversion pouchitis successfully treated with leukocyteapheresis. Ther Apher Dial 2014; 18:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyabanga CT, Shen B. Endoscopic Treatment of Bleeding Diversion Pouchitis with High-Concentration Dextrose Spray. ACG Case Rep J 2017; 4:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen B, Kochhar GS, Navaneethan U, et al. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol 2021; 6:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasan B, Khalid R, Charles R, Shen B. Abdominal Pain in a Patient With Diverted Bowel and Inflammatory Bowel Disease. ACG Case Rep J 2020; 7:e00437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen B, Kochhar G, Navaneethan U, et al. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol 2020; 5:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lan N, Shen B. Endoscopic Stricturotomy with Needle Knife in the Treatment of Strictures from Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23:502.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139633 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7450438" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Proctitis and colitis following diversion of the fecal stream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7450438" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Proctitis and colitis following diversion of the fecal stream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23382634" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relationship between diversion colitis and quality of life in rectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26243588" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diversion proctocolitis and response to treatment with short-chain fatty acids--a clinicopathological study in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3980962" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The fate of the rectal segment after diversion of the fecal stream in Crohn's disease: its implications for surgical management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8472988" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diversion colitis and involution of the defunctioned anorectum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2909876" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Treatment of diversion colitis with short-chain-fatty acid irrigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25306934" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Factors affecting the fate of faecal diversion in patients with perianal Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6745620" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Proctitis after fecal diversion in Crohn's disease and its elimination with reanastomosis: implications for surgical management. Report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27096767" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The usefulness of anorectal manometry in patients with a stoma before and after surgery to restore the continuity of the gastrointestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28357500" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Diversion colitis 25 years later: the phenomenon of the disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34774224" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720118" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1914718" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26607831" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353052" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11584399" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Diversion procto-colitis: response to treatment with short-chain fatty acids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7851194" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1595655" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A case of diversion colitis treated with 5-aminosalicylic acid enemas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27403119" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Efficacy of Combined Mesalazine Plus Corticosteroid Enemas for Diversion Colitis after Subtotal Colectomy for Ulcerative Colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30085111" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34076248" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Is Intestinal Diversion an Effective Treatment for Distal Crohn's Disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23188592" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Transanal endoscopic microsurgery approach for rectal stump resection as an alternative to transperitoneal stump resection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33917556" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Diversion Colitis: Macro and Microscopic Findings after Probiotics Stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25300242" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Successful autologous fecal transplantation for chronic diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34751848" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Autologous fecal transplant for the treatment of microcolon due to diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35310733" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34008743" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Tissue content of metalloproteinase-9 and collagen in the colon with and without fecal stream after intervention with infliximab in rats subjected to Hartmann's surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34598959" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Novel application of infliximab for diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25252200" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of the application of enemas containing sucralfate in tissue content of neutral and acid mucins in experimental model of diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34852133" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and ?-catenin in colonic mucosa without fecal stream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24287143" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ascidian (chordate-tunicate) and mammalian heparin enemas attenuate experimental diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14962686" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intraluminal irrigation with fibers improves mucosal inflammation and atrophy in diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27237942" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anti-inflammatory effects of enemas containing an oily extract of curcumin in an experimental model of diversion colitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24571541" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Chronic antibiotic-refractory diversion pouchitis successfully treated with leukocyteapheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28377939" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Endoscopic Treatment of Bleeding Diversion Pouchitis with High-Concentration Dextrose Spray.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33872568" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32821767" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Abdominal Pain in a Patient With Diverted Bowel and Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31954438" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28296818" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Endoscopic Stricturotomy with Needle Knife in the Treatment of Strictures from Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
